Avastin.net

All patient subgroups can benefit from Avastin

PFS benefit was consistent across patient subgroups in two phase III trials in mBC^9,14

• Many different factors can affect the outcome of therapy in cancer patients, but as VEGF is essential for tumour angiogenesis, it is predicted that all patient subgroups should benefit from Avastin.

• In the pivotal phase III trial in mCRC, OS benefit was observed in all patient subgroups, independent of baseline risk factors such as performance status, number of metastatic sites and adjuvant chemotherapy.²¹

• Avastin also benefited all patient subgroups in two phase III studies in non-squamous NSCLC^8,12
  • one study found particular OS benefit in patients with adenocarcinoma (HR=0.69); sample sizes for other histologies were small, making data for these inconclusive.²²

• Subgroup analyses from two phase III studies of Avastin plus chemotherapy in first-line mBC have demonstrated PFS benefit due to Avastin in all prespecified patient subgroups, including those based on age, disease-free interval, number of metastatic sites and prior therapy.^9,14,23

• In RCC, benefit from Avastin plus IFN-α was independent of baseline characteristics, including MSKCC risk score, which groups patients according to prognostic factors.¹⁰